Bharat Parenterals Ltd

Bharat Parenterals operates with a current ratio of 1.62, indicating moderate liquidity, but its operating cash flow of -INR 272.54 million and free cash flow of -INR 379.64 million suggest ongoing cash flow challenges. The company's debt-to-equity ratio of 0.54 reflects a relatively conservative capital structure, though its net income of -INR 126.26 million and operating income of -INR 315.72 million indicate a lack of profitability. The company's return on equity of -3.82% and return on assets of -1.95% are significantly below the industry median for pharmaceutical firms, which typically report positive ROE and ROA. This underperformance suggests inefficiencies in asset utilization and equity generation, which could be a concern for investors. Bharat Parenterals' revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's client base includes small biopharmaceutical startups and pharmaceutical companies, but there is no indication of revenue concentration by region or major customer. The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. The lack of profitability and negative cash flows may limit its ability to invest in R&D or expand its product portfolio. The outlook for the next fiscal year is not provided, but the current financial performance suggests a challenging path forward. The risk assessment highlights medium liquidity risk and low dilution risk. The company's net cash position is negative after subtracting total debt, which could constrain its ability to meet short-term obligations. There is no indication of dilution potential in the near term, but the company's financial position may require additional capital in the future. Recent events include the company's latest financial filing, which discloses a net loss and negative cash flows. There are no recent transcripts or press releases indicating significant operational or strategic developments.